Background. Pain on injection is a major disadvantage of propofol, experien
ced by the vast majority of patients. Since the traditional formulation has
almost normal osmolality and pH, it is hypothesised that the concentration
of free propofol in the aqueous phase of the emulsion is responsible for t
he pain and that reducing the amount of free propofol would also reduce the
frequency and intensity of pain on injection. This study was designed to i
nvestigate whether pain on injection can be reduced in frequency and intens
ity by a new formulation of propofol.
Methods. We performed a monocentre, controlled, randomised, double-blind st
udy to compare the pain produced by intravenous injection of a new propofol
preparation (propofol-MCT/LCT) with standard propofol in patients undergoi
ng elective surgical procedures. A total of 184 non-premedicated patients r
eceived either 1% propofol prepared in a mixture of medium and long chain t
riglycerides (Propofol-MCT/LCT, Propofol-(R) Lipuro, B. Braun Melsungen AG)
or standard 1% propofol prepared exclusively in long chain triglycerides (
Propofol-LCT; Disoprivan (R) ,AstraZeneca) into a vein of the dorsal hand f
or induction of anaesthesia. Anaesthesia was maintained by TIVA with propof
ol and remifentanil. Pain on injection was recorded and graded as none, mil
d, moderate or severe.
Results. Patients receiving propofol-MCT/LCT had a significantly lower inci
dence of pain on injection compared to the standard propofol group (37% vs
64%) with the intensity of pain also being less severe. There were no diffe
rences between both groups in propofol dosage for induction (3.2 +/-0.8 mg/
kg vs 3.3 +/-0.9 mg/kg) and maintenance of anaesthesia (3.4 +/-0.6 mg/kg/h
vs 3.2 +/-0.5 mg/kg/h), remifentanil dosage (25 +/-6 mug/kg/h vs. 24 +/-6 N
g/kg/h), intraoperative hemodynamics,recovery parameters and postoperative
patient satisfaction. Postoperative thrombophlebitis at the injection site
for propofol was not observed in any of the patients. Conclusions. Propofol
-MCT/LCT produced significantly less pain on injection when compared to sta
ndard propofol in ASA I and II patients undergoing elective surgery. Pain w
as also significantly less severe,with both effects presumably being due to
the lower concentration of free propofol in the MCT/LCT-preparation. With
regard to injection pain propofol-MCT/LCT offers significant a advantage ov
er standard propofol.